First Page | Document Content | |
---|---|---|
![]() Date: 2016-07-27 08:19:27Neurochemistry Medicine Clinical medicine Complement deficiency RTT Sodium channel blockers Euphoriants Calcium channel blockers Hereditary angioedema Syringe Angioedema Ketamine | Add to Reading List |
![]() | [Product Monograph Template - Schedule D]DocID: 1qWQL - View Document |
![]() | News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web SitesDocID: 1qHpD - View Document |
![]() | Microsoft Word - CINRYZE.Product MonographdocDocID: 1qE2h - View Document |
![]() | Microsoft Word - FIRAZYR.Product MonographdocDocID: 1qA9x - View Document |
![]() | Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we developDocID: 1pVHk - View Document |